Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$248,025.00

Precision medicine in breast cancer: from the computer to the clinic

EF 2017-18

Résumé
Breast cancer is the second leading cause of cancer deaths in Canadian women, with 23,800 new cases and an estimateddeath rate of 21% in Canada in 2013. The advent of personalized medicine, which consists of using molecular data(mutations in cancer-related genes for instance) to tailor treatment to the individual patient, holds the promise to significantlyimprove cancer management in our modern society. However, while thousands of anticancer drugs have been developed,few of them were translated into efficient therapeutic strategies in breast cancer. The primary reason for such a discrepancyis the inability to predict patients response to a given therapeutic drug. There is therefore a dire need for developing newclinical tests that can help clinicians select the most beneficial therapy for each individual breast cancer patient.Predicting drug response is a challenging task due to the complex nature of breast cancer. New molecular features enablingprediction of therapy response, are usually discovered using either immortalized cancer cells or patients tumor biopsies.More recently, patient-derived xenografts (PDX) where human tumors are implanted in mice, also enabled to test drugs in amodel that recapitulate most of the features of real patients tumors. These preclinical models have their own weaknessesand strengths. To date these data have never been combined to develop accurate predictors of drug response. We proposein our project to use our recently published network-based method called SNF to efficiently combine cancer cell lines, PDXand patients tumors to build better predictors of drug response and test them in new patients samples collected withinongoing clinical trials. Upon successfully validation, we will closely work with our collaborators to implement our newcomputational tool in clinical routine with the aim to improve matching of patients to the clinical trials testing the drugs fromwhich they most benefit.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
493626-2016
Name nom
HaibeKains, Benjamin
Department département
Medical Biophysics
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
248025
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Precision medicine in breast cancer: from the computer to the clinic
Keyword
NSERC
Application summary
Breast cancer is the second leading cause of cancer deaths in Canadian women, with 23,800 new cases and an estimateddeath rate of 21% in Canada in 2013. The advent of personalized medicine, which consists of using molecular data(mutations in cancer-related genes for instance) to tailor treatment to the individual patient, holds the promise to significantlyimprove cancer management in our modern society. However, while thousands of anticancer drugs have been developed,few of them were translated into efficient therapeutic strategies in breast cancer. The primary reason for such a discrepancyis the inability to predict patients response to a given therapeutic drug. There is therefore a dire need for developing newclinical tests that can help clinicians select the most beneficial therapy for each individual breast cancer patient.Predicting drug response is a challenging task due to the complex nature of breast cancer. New molecular features enablingprediction of therapy response, are usually discovered using either immortalized cancer cells or patients tumor biopsies.More recently, patient-derived xenografts (PDX) where human tumors are implanted in mice, also enabled to test drugs in amodel that recapitulate most of the features of real patients tumors. These preclinical models have their own weaknessesand strengths. To date these data have never been combined to develop accurate predictors of drug response. We proposein our project to use our recently published network-based method called SNF to efficiently combine cancer cell lines, PDXand patients tumors to build better predictors of drug response and test them in new patients samples collected withinongoing clinical trials. Upon successfully validation, we will closely work with our collaborators to implement our newcomputational tool in clinical routine with the aim to improve matching of patients to the clinical trials testing the drugs fromwhich they most benefit.